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Abstract
Objective—To evaluate the performance of the Human Papillomavirus High-Risk DNA test in
patients 30 years and older.
Materials and Methods—Screening (N=835) and diagnosis (N=518) groups were defined based
on prior Papanicolaou smear results as part of a clinical trial for cervical cancer detection. We
compared the Hybrid Capture II® (HCII) test result to the worst histological report. We used cervical
intraepithelial neoplasia (CIN) 2/3 or worse as the reference of disease. We calculated sensitivities,
specificities, positive and negative likelihood ratios (LR+ and LR−), receiver operating characteristic
(ROC) curves, and areas under the ROC curves for the HCII test. We also considered alternative
strategies, including Papanicolaou smear, a combination of Papanicolaou smear and the HCII test, a
sequence of Papanicolaou smear followed by the HCII test, and a sequence of the HCII test followed
by Papanicolaou smear.
Results—For the screening group, the sensitivity was 0.69 and the specificity was 0.93; the area
under the ROC curve was 0.81. The LR+ and LR− were 10.24 and 0.34, respectively. For the
diagnosis group, the sensitivity was 0.88 and the specificity was 0.78; the area under the ROC curve
was 0.83. The LR+ and LR− were 4.06 and 0.14, respectively. Sequential testing showed little or no
improvement over the combination testing.
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Conclusions—The HCII test in the screening group had a greater LR+ for the detection of CIN
2/3 or worse. HCII testing may be an additional screening tool for cervical cancer in women 30 years
and older.
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INTRODUCTION
Current U.S. guidelines recommend that human papillomavirus (HPV) testing be used after an
abnormal Papanicolaou smear (specifically, when the result is ASCUS, atypical squamous cells
of uncertain significance) or as a screening tool for cervical dysplasia in patients 30 years and
older (1,2).
Although the HPV test is recommended as a screening test, few clinical trials evaluating the
accuracy of the tests available in the market have been conducted in screening populations. A
recent review identified 25 non-randomized trials evaluating the HPV test as the primary
screening tool for cervical cancer, and among those, only 4 studies adjusted for verification
bias by referring all participants to receive a colposcopy and biopsy (3). Studies failing to
correct for verification bias tend to overestimate sensitivity and underestimate specificity.
Adjusting for verification bias by using histology in a screening trial may be difficult due to
the incomplete follow-up of participants and their refusal to accept biopsies after a negative
test. If participants are referred to colposcopy, biopsies are typically taken only from tissue of
abnormal appearance. In this situation, because of the low sensitivity of colposcopy in
screening populations, a participant may be considered a true negative for disease and not
receive verification of disease status through histology when in fact the colposcopic
examination of the participant was normal.
In a randomized trial comparing the performance of the HPV test to that of the Papanicolaou
smear in a screening population, researchers found that the sensitivity of the HPV test dropped
from 83% to 46% when adjusting for verification bias (4). These results did not show a
substantial advantage of the HPV test over the Papanicolaou smear (adjusted sensitivity 43%),
although the reported specificity of the HPV test was substantial.
The accuracy of the Papanicolaou smear has been challenged due to the rate of false negative
results that lead to missed cases of advanced cervical disease. Although the HPV test has been
considered a reasonable alternative due to its high sensitivity, recent research shows conflicting
results regarding the test's operating characteristics.
To evaluate the test's potential as a screening tool for cervical cancer, the performance of the
HPV test needs to be studied in diverse settings and adjusted for verification bias. We aimed
to evaluate the performance of the HPV High-Risk DNA test, a particular form of HPV testing,
for oncogenic types of HPV in women 30 years and older recruited from screening and
diagnostic settings.
MATERIALS AND METHODS
We studied women participating in a phase II clinical trial to evaluate fluorescence and
reflectance spectroscopy, an emerging technology for the detection of cervical pre-cancer that
uses an optical probe to inspect the cervix. Nonpregnant women age 18 and older were enrolled
in this trial from October 1998 to November 2005. Women were allocated to a screening group
if they stated that they had no history of abnormal Papanicolaou smear results; women were
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allocated to a diagnosis group if they stated that they had had an abnormal Papanicolaou smear
at any previous time. Women were excluded from participation in the study if they had a history
of cervical cancer or cervical intraepithelial neoplasia (CIN). The trial was conducted at three
clinical locations: a comprehensive cancer center in the United States (The University of Texas
M. D. Anderson Cancer Center), a community general hospital in the United States (Lyndon
Baines Johnson Hospital Health District), and a cancer center in Canada (British Columbia
Cancer Agency).
Advertising in the local media was one of the strategies used to increase the participation of
women from local communities, and the strategy was expected to be effective in increasing
the participation of minorities. Details of the recruitment strategies and the socio-demographic
characteristics of the women have previously been reported (5). The study protocol was
approved by the Institutional Review Boards of the three clinical locations. The women
provided informed consent before participating in the trial.
The clinical trial protocol included a complete clinical exam as well as several tests routinely
used for the screening and detection of gynecological disease. Each woman provided a
complete medical history, including an interview to assess cervical cancer risk factors, and was
given a physical and pelvic exam. The pelvic exam included a conventional Papanicolaou
smear, cervical cultures to test for Chlamydia and gonorrhea, specimens for HPV testing, and
a colposcopic examination of the vulva, vagina, and cervix, including two to four fluorescence
and spectroscopic measurements.
After the fluorescence and spectroscopic measurements were performed, biopsies were
obtained from colposcopic abnormal sites and from normal sites. If there was an area of
abnormal colposcopic impression, the colposcopist took one or two colposcopically directed
biopsies of the area with the worst overall colposcopic impression, as is done in usual care.
The colposcopist also took one or two biopsies of squamous and columnar epithelium from an
area of normal appearance, typically at the 6 o'clock and 12 o'clock positions, whether an
abnormal area was identified with colposcopy or not. At the time of the conventional
Papanicolaou smear, endocervical and ectocervical samples were obtained and used to prepare
the conventional smear sample. Cells for the HPV test were then obtained by immersing the
cervical brush in a 0.9% sodium chloride sterile solution vial.
HPV High-Risk DNA Testing
We selected the High-Risk DNA test, a particular form of HPV test, using the Food and Drug
Administration-approved Hybrid Capture II® (HCII) test (Digene Corporation, Gaithersberg,
Maryland). The test was performed by a clinical laboratory (Laboratory Corporation of
America®) using the standardized procedure recommended by the test manufacturer.
In performing the HCII test, HPV DNA was denatured and then incubated with two RNA
probes (probe B for high-risk types and probe A for low-risk types), resulting in the formation
of RNA-DNA hybrids. The hybrids were captured by antibodies against RNA-DNA hybrids
bound to a solid phase, and any unbound hybrids were washed off. Antibodies conjugated to
alkaline phosphatase were allowed to attach to the hybrids. The chemiluminescent product
obtained from the conjugated antibody-hybrid constructs corresponded to the amount of DNA
in the sample, was measured by a luminometer, and was reported in relative light units (RLUs).
A test was considered positive for high-risk types if, for probe B, the RLUs of the sample were
equal to or greater than the mean RLUs of the positive control, which was equivalent to 1
picogram of HPV high-risk DNA per milliliter. A negative control was used to evaluate
negative tests.
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Definition of Disease for Purposes of Clinical Epidemiological Analysis
For the gold standard of “disease,” we selected the worst histological report from among all
of the biopsies obtained for each woman. We defined “disease” as CIN 2/3 or worse, which is
the disease threshold used in clinical practices for the treatment of patients.
All specimens were read twice at the study site by pathologists blinded to the women's clinical
history. If the readings disagreed, the biopsy was read by a third pathologist. Details on the
high level of agreement among participating pathologists have been previously published (6).
Statistical Analysis
We compared the sociodemographic characteristics (age, race, education, marital status, and
employment), clinical characteristics (Papanicolaou smear result, menopausal status, and
gravidity), and risk factors (smoking and alcohol intake) of the screening and diagnosis groups.
The Student's t-test was used to determine the differences in age by study group, and the Pearson
chi-squared test was used to analyze categorical variables.
We initially determined the prevalence of CIN 2/3 or worse for the screening group based on
the histology. Within the screening group, we evaluated the performance of the HCII test, the
Papanicolaou smear, and a combination of the HCII test and the Papanicolaou smear (for which
an abnormal result was defined as a Papanicolaou smear result of ASCUS or worse or a positive
HCII test). We then evaluated the performance of the HCII test in the subgroup of women with
Papanicolaou smear results of ASCUS or worse. Finally, we evaluated the performance of the
Papanicolaou smear in the subgroup of women with positive HCII tests. We then recomputed
the prevalence of CIN 2/3 or worse for these subgroups (i.e. after an initial abnormal test result)
within the screening group.
For each test or test combination, we determined the sensitivity, specificity, and respective
95% confidence intervals and computed the positive likelihood ratio (LR+) and negative
likelihood ratio (LR−). We then calculated positive and negative predictive values for each
group of women based on the prevalence, sensitivity, and specificity of the tests.
We repeated the above analyses for the diagnosis group. We constructed receiver operating
characteristic (ROC) curves for the HCII test in the screening and diagnosis groups and
compared the areas under the curves using a chi-squared test with a nonparametric approach,
as suggested by DeLong et al. (7).
We used SPSS© 12.0 for Windows (SPSS Inc., Chicago, Illinois) and Stata version 9 statistical
software (StataCorp LP, College Station, Texas) for the statistical analysis.
RESULTS
We enrolled 1000 women with a history of normal Papanicolaou smears into the screening
group and 850 women with a history of abnormal smears into the diagnosis group. In
accordance with clinical practice guidelines, we then considered only those women who were
30 and older, which left 873 and 571 in the screening and diagnosis groups, respectively. Of
those, we excluded women who did not have results from both an HCII test and an internal
Papanicolaou smear; we also excluded women who did not have histology results. These steps
left 835 women in the screening group and 518 women in the diagnosis group with complete
data for the analysis. More women had missing data in the diagnosis group (9.3%) than in the
screening group (4.4%), and the difference was significant (p < 0.001; see Figure 1).
Most of the women 30 years and older with complete data (61.7%) were recruited into the
screening group. Women in this group tended to be older than those in the diagnosis group
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(46.7 years vs. 42.3 years, respectively; p < 0.001). Significant differences in race, marital
status, smoking habits, and menopausal status were observed between the groups. The
prevalence of abnormal Papanicolaou smears (ASCUS and worse) in the screening group and
the diagnosis group was 7.1% and 40.2%, respectively. Details are shown in Table 1.
Table 2 presents the frequencies of histology and test results in the screening and diagnosis
groups. For the screening group, the HCII test had a sensitivity of 0.69 and a specificity of
0.93. The LR+ and LR− were 10.24 and 0.34, respectively. In the diagnosis group, the
sensitivity was 0.89 and the specificity was 0.78. The LR+ and LR− in this group were 4.06
and 0.14, respectively (see Table 3).
We constructed a ROC curve for each of the study groups and estimated the area under each
curve (see Figure 2). The area under the ROC curve for the screening group was 0.81 (95% CI
0.78, 0.84) and the area under the ROC curve for the diagnosis group was 0.83 (95% CI 0.80,
0.87). The two curves were not statistically different (p = 0.69).
The results for testing with the Papanicolaou smear alone were slightly worse than the results
for the HCII test alone. For the Papanicolaou smear alone, the sensitivities were lower and the
specificities were approximately the same in the screening and diagnosis groups. The areas
under the curve were lower for the Papanicolaou smear alone compared to the HCII test alone;
similarly, the likelihood ratios were inferior for the Papanicolaou smear alone compared to the
HCII test alone, although the positive likelihood ratio for the screening group was 6.89.
In the screening group, the operating characteristics of the combination of the Papanicolaou
smear and the HCII test were the same as for the HCII test alone because all of the women who
had an abnormal Papanicolaou smear also had a positive HCII test. In the diagnosis group, the
sensitivity improved to 0.96 (95% CI 0.92, 0.99) but the specificity decreased to 0.65 (95% CI
0.60, 0.69). In that case, the predictive value negative (PVN = 0.98) was the lowest of any test
sequence.
We then considered the use of a reference test. When the reference test was the Papanicolaou
smear, we found that 47 women in the screening group had an abnormal result of ASCUS or
worse. The HCII test was positive for all women who had CIN 2/3 or worse (7/47). With this
small sample size, the conditional sensitivity was 1.00 (one-sided 97.5% CI 0.59, 1.00) and
the conditional specificity was 0.65 (95% CI 0.48, 0.79). The area under the ROC curve was
0.82. In the diagnosis group, for the women who had an abnormal Papanicolaou smear, the
HCII test had a conditional sensitivity of 0.90 (95% CI 0.82, 0.95) and a conditional specificity
of 0.41 (95% CI 0.31, 0.52). The area under the ROC curve was 0.66.
When evaluating the performance of the Papanicolaou smear to detect CIN 2/3 or worse after
an HCII reference test, we found for both the screening and diagnosis groups that the
conditional sensitivity was worse than the respective situations examined when the
Papanicolaou smear was the reference test. In addition, the respective areas under the ROC
curves and the positive and negative likelihood ratios were worse when the HCII test was the
reference test compared to when the Papanicolaou smear was the reference test. Details can be
found in Table 3.
DISCUSSION
We found superior accuracy of the HCII test to detect CIN 2/3 or worse in the screening group.
No significant difference was observed between the areas under the ROC curves for the
screening and diagnosis groups, but a higher LR+ was observed in the screening group when
compared to the diagnosis group (10.24 vs. 4.06, respectively).
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This finding points toward the use of the HCII test as an alternative to the Papanicolaou smear
for the screening of cervical cancer in similar populations. Other researchers have reported
results similar to ours. A recent randomized clinical trial conducted by Mayrand et al. (4)
compared the HCII test to the Papanicolaou smear and reported the performance of both tests
in a screening population. Considering their definition of disease and use of strategies to correct
verification bias, their results may be comparable to our screening group results. Mayrand et
al. (4) defined two categories of disease: liberal and conservative. The former was defined
using any histologic result available from the colposcopically-directed biopsies or loop
electrosurgical excision procedure (LEEP) specimens, and the latter was defined using only
LEEP specimens. In this way, their liberal definition of disease is more like the definition used
in our study, which allows us to compare the two sets of results. Similar to our study, the
researchers implemented strategies to reduce verification bias by confirming the histology
diagnosis in a random sample of participants with negative tests reporting the crude and
corrected operating characteristics of the HCII. Using the liberal definition of disease, Mayrand
et al. (4) reported a sensitivity of 82.8% and a specificity of 61.1% as the crude operating
characteristics of the HCII test, and a sensitivity of 45.9% and a specificity of 94.2% as the
corrected operating characteristics of the HCII test.
The sensitivity in our screening group was higher than the adjusted sensitivity reported by
Mayrand et al. (4) (68.8% vs. 45.9%, respectively). The differences in our results may be
explained by the study sampling and the natural history of HPV infection. While women in
our study were allocated into a screening or diagnosis group based on their history of
Papanicolaou smear results, participants in the Mayrand et al. (4) study were recruited from a
screening program. Indeed, Mayrand et al. (4) reported that approximately 28% of the
participants had a history of abnormal Papanicolaou smears, and 2% had never been tested.
Thus, participants in the Mayrand et al. (4) study may have been infected with HPV at the time
of the first abnormal test and had an increased length of exposure to the HPV virus compared
to our group of women with a history of normal smears.
Differences in the performance of the HCII test have also been explained by local differences
in the processing and handling of samples, as suggested by Sankaranarayanan et al. while
conducting a multicenter study of the HCII test in India (8). The three other studies that avoided
verification bias (9-11) showed operating characteristics that were quite similar to the ones
found in our study. Small variations exist, which may indicate that the test as used in our study
was operating at a different point on the hypothetically same ROC curve.
Our evaluation of HCII test performance may not reflect actual clinical practice because not
all patients in a screening group are referred to colposcopy, and biopsies are not usually
obtained from tissue of normal colposcopic appearance. Moreover, endocervical curettages are
not performed in screening populations. While our study methods helped to establish the
disease or non-disease status of each woman, they may have increased the detection of small
lesions that are not usually discovered when performing a routine colposcopic examination.
Current U.S. guidelines for cervical cancer screening suggest that the tests can be used
simultaneously in women over 30 years old with the option of extending the screening intervals
up to every three years if both tests are negative. Our data, in fact, support the use of the HCII
test in conjunction with the Papanicolaou smear rather than as a follow-up test for an abnormal
cytological test. We observed the best sensitivity and specificity with the concurrent use of
either the Papanicolaou smear or the HCII test with near perfect predictive value negative.
Even the use of the HCII test alone in either the screening group or the diagnosis group
generated superior sensitivity and specificity when compared to previous reports for
Papanicolaou testing alone. Additional issues, such as economic and epidemiological
considerations, would need to be considered before making evidence-based guidelines for
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public policy. These questions are particularly relevant for determining policy in limited
resource settings.
The HCII test is limited to detecting the 13 most common HPV high-risk viral strains associated
with cervical cancer, and cannot determine specific viral strains. Moreover, a false negative
result may be caused by the presence of small numbers of viral copies in the study sample.
From the perspective of epidemiological studies, the test may provide a general overview of
the prevalence of infection with high-risk viral strains, but the distribution of each high-risk
strain in a study population needs to be addressed using other tests that are not clinically
approved.
Using the HCII test, we have demonstrated the potential of HPV testing in two subgroups of
women. There is greater potential for clinical applicability using the HCII test for women in a
screening population than in a diagnosis population. The operating characteristics of the HCII
test seem superior when compared to those of the conventional Papanicolaou smear, and are
perhaps competitive with liquid-based technologies. For a screening population, we would like
to minimize the number of false positives that would require additional testing or intervention.
Since cervical cancer is fairly slow in developing, a lower sensitivity can be accommodated
by repeated screening. However, we want to minimize false negatives for a diagnosis
population which has likely experienced previous cytological abnormalities and is likely to be
at an increased risk for future abnormalities. This allows for minimal numbers of missed
diagnoses. In addition, the use of the HCII test alone in this population may cause some
pathologies to be missed; this could be avoided by adding cytological screening to HPV DNA
testing. Our results support the use of the HCII test in screening for cervical dysplasia.
However, further study may be required to determine whether the use of HPV testing as a
primary screening tool for cervical pre-cancer should become standard practice.
ACKNOWLEDGEMENTS
The authors thank Rebecca Partida for editorial contributions that enhanced the clarity of the manuscript.
Financial support for this study was provided by grant number CA82710 from the National Cancer Institute. The
funding agreement ensured the authors' independence in designing the study, interpreting the data, and writing and
publishing the report.
REFERENCES
1. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management
Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet
Gynecol 2005;105:905–18. [PubMed: 15802436]
2. Wright TC Jr. Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the
Management of Women with Cervical Cytological Abnormalities. J Low Genit Tract Dis 2002;6:127–
43. [PubMed: 17051012]
3. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic
accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-
analysis of non-randomized studies. Gynecol Oncol 2007;104:232–46. [PubMed: 17084886]
4. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou
screening tests for cervical cancer. N Engl J Med 2007;357:1579–88. [PubMed: 17942871]
5. Pham B, Earle N, Rabel K, Follen M, Scheurer ME. Maximizing the diversity of participants in a phase
II clinical trial of optical technologies to detect cervical neoplasia. Gynecol Oncol 2007;107:208–14.
6. Malpica A, Matisic JP, Niekirk DV, et al. Kappa statistics to measure interrater and intrarater agreement
for 1790 cervical biopsy specimens among twelve pathologists: qualitative histopathologic analysis
and methodologic issues. Gynecol Oncol 2005;99:S38–52. [PubMed: 16183106]
Cárdenas-Turanzas et al. Page 7
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2009 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
7. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated
receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.
[PubMed: 3203132]
8. Sankaranarayanan R, Chatterji R, Shastri SS, et al. Accuracy of human papillomavirus testing in
primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer
2004;112:341–7. [PubMed: 15352050]
9. Blumenthal PD, Gaffikin L, Chirenje ZM, McGrath J, Womack S, Shah K. Adjunctive testing for
cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int J Gynaecol
Obstet 2001;72:47–53. [PubMed: 11146077]
10. Pan Q, Belinson JL, Li L, et al. A thin-layer, liquid-based pap test for mass screening in an area of
China with a high incidence of cervical carcinoma. A cross-sectional, comparative study. Acta Cytol
2003;47:45–50. [PubMed: 12585030]
11. Coste J, Cochand-Priollet B, de Cremoux P, et al. Cross sectional study of conventional cervical
smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening.
BMJ 2003;326:733. [PubMed: 12676841]
Cárdenas-Turanzas et al. Page 8
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2009 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
Flow diagram for patient recruitment and data analysis.
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Figure 2.
Comparison of receiver operating characteristic (ROC) curves for Hybrid Capture II (HCII)
test used in the screening and diagnosis groups with definition of disease as cervical
intraepithelial neoplasia (CIN) 2/3 or worse.
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Table 1
Demographic and Clinical Characteristics of Participants 30 Years and Older
Screening Group
N (%)
Diagnosis Group
N (%)
p-value
Total 835 (61.7) 518 (38.3) < 0.001
Age (mean) 46.7 42.3 < 0. 001
Race < 0. 001
     Non-Hispanic white 427 (51.1) 331 (63.9)
     African American 123 (14.7) 49 (9.5)
     Hispanic 218 (26.1) 71 (13.7)
     Asian 55 (6.6) 48 (9.3)
     Other 12 (1.4) 19 (3.7)
Education 0.35
     High School or less 200 (24.0) 144 (27.8)
     Some college 321 (38.4) 178 (34.4)
     College 192 (23.0) 119 (23.0)
     Graduate education 122 (14.6) 77 (14.9)
Marital status 0.16
     Married or married-like situation 515 (61.7) 280 (54.1)
     Never married 126 (15.1) 86 (16.6)
     Divorced or separated 170 (20.4) 137 (26.4)
     Widowed 24 (2.9) 13 (2.5)
     Unknown 0 (0.0) 2 (0.4)
Employment 0.16
     Employed (full or part time) 568 (68.0) 371 (71.6)
Ever smoked < 0.001
     Yes 291 (34.9) 226 (43.6)
Current smoker < 0.001
     Yes 82 (9.8) 107 (20.7)
Drink alcohol 0.15
     Yes 545 (65.3) 364 (70.3)
Number of pregnancies 0.63
     None 139 (16.6) 96 (18.5)
     1-3 476 (57.0) 293 (56.6)
     More than 3 220 (26.3) 129 (24.9)
Menopause < 0.001
     Premenopausal 426 (51.0) 390 (75.3)
     Postmenopausal 284 (34.0) 106 (20.5)
     Perimenopausal 124 (14.9) 22 (4.2)
Papanicolaou smear result < 0.001
     Normal 776 (92.9) 310 (59.8)
     ASCUS 12 (1.4) 15 (2.9)
     LGSIL 35 (4.2) 72 (13.9)
     HGSIL and cancer 12 (1.4) 121 (23.4)
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